KUMAR ABHISHEK
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- MECHANICSVILLE, VA
- NPI
- 1083827018
- Received
- $1,044,344 in 1,516 records, 2019 to 2025
- As principal investigator
- $961 of research payments to others in 9 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 180 | $204,756 |
| 2024 | General payment | 190 | $235,907 |
| 2023 | General payment | 207 | $120,920 |
| 2022 | General payment | 265 | $163,536 |
| 2021 | General payment | 203 | $102,654 |
| 2020 | General payment | 167 | $46,534 |
| 2019 | General payment | 304 | $170,032 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 283 | $728,083 |
| Consulting Fee | 81 | $153,966 |
| Travel and Lodging | 207 | $110,255 |
| Food and Beverage | 880 | $32,849 |
| Honoraria | 9 | $15,455 |
| Long term medical supply or device loan | 36 | $3,032 |
| Education | 19 | $352 |
| Grant | 1 | $350 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | E.R. Squibb & Sons, L.L.C. | $3,185 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-30 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-12-23 | Daiichi Sankyo Inc. | $97 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-12-16 | AstraZeneca Pharmaceuticals LP | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | GENZYME CORPORATION | $2,943 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SARCLISA Biological, Oncology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $111 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-12-15 | Daiichi Sankyo Inc. | $822 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $85 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $1,191 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-12-05 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-12-05 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-12-04 | Caris MPI, Inc. | $23 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-11-28 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-11-26 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-11-24 | E.R. Squibb & Sons, L.L.C. | $3,185 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-11-19 | AstraZeneca Pharmaceuticals LP | $2,010 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-11-18 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-18 | Daiichi Sankyo Inc. | $102 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-18 | Daiichi Sankyo Inc. | $31 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-18 | GENZYME CORPORATION | $19 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-18 | Daiichi Sankyo Inc. | $15 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-13 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $95 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-11 | Incyte Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $538 | Travel and Lodging | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-11-10 | JAZZ PHARMACEUTICALS INC. | $4,472 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-06 | Incyte Corporation | $985 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-06 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-04 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-04 | Daiichi Sankyo Inc. | $293 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-04 | Daiichi Sankyo Inc. | $175 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-04 | Daiichi Sankyo Inc. | $128 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-11-03 | AstraZeneca Pharmaceuticals LP | $3,015 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-11-03 | JAZZ PHARMACEUTICALS INC. | $121 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-30 | JAZZ PHARMACEUTICALS INC. | $1,093 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-27 | GENZYME CORPORATION | $2,943 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SARCLISA Biological, Oncology | 2025 | |
| 2025-10-27 | GENZYME CORPORATION | $81 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-10-25 | AstraZeneca Pharmaceuticals LP | $322 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-10-25 | AstraZeneca Pharmaceuticals LP | $50 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-10-25 | AstraZeneca Pharmaceuticals LP | $50 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $483 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-23 | Tempus AI, Inc | $29 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-10-16 | Incyte Corporation | $825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-15 | Daiichi Sankyo Inc. | $502 | Consulting Fee | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-14 | Incyte Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-14 | Incyte Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-10 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-09 | Incyte Corporation | $938 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-09 | Incyte Corporation | $123 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-07 | Daiichi Sankyo Inc. | $977 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-07 | AstraZeneca Pharmaceuticals LP | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-07 | Daiichi Sankyo Inc. | $99 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-02 | Caris MPI, Inc. | $24 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $2,010 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-30 | Incyte Corporation | $123 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $83 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $31 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $15 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $15 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-29 | E.R. Squibb & Sons, L.L.C. | $2,012 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-26 | Daiichi Sankyo Inc. | $4,690 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-26 | AstraZeneca UK Limited | $1,005 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-23 | Daiichi Sankyo Inc. | $328 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-23 | Daiichi Sankyo Inc. | $128 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-19 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-16 | E.R. Squibb & Sons, L.L.C. | $787 | Travel and Lodging | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $171 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-15 | MicroVention, Inc. | $25 | Food and Beverage | In-kind items and services | SOFIA 6F-131CM STR Device, NEUROLOGICAL PRODUCT | 2025 | |
| 2025-09-11 | JAZZ PHARMACEUTICALS INC. | $5,031 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-09-11 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-08-26 | AstraZeneca Pharmaceuticals LP | $2,680 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-23 | JAZZ PHARMACEUTICALS INC. | $97 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-23 | JAZZ PHARMACEUTICALS INC. | $91 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-23 | JAZZ PHARMACEUTICALS INC. | $30 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-23 | JAZZ PHARMACEUTICALS INC. | $15 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-22 | JAZZ PHARMACEUTICALS INC. | $204 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-22 | JAZZ PHARMACEUTICALS INC. | $149 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-15 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-14 | Adaptive Biotechnologies Corporation | $26 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-08-14 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-08-14 | E.R. Squibb & Sons, L.L.C. | $14 | Travel and Lodging | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $1,038 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-08 | E.R. Squibb & Sons, L.L.C. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-05 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $1,089 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $104 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-26 | Astellas Pharma US Inc | $342 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-07-25 | Incyte Corporation | $5,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $2,345 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-25 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-24 | E.R. Squibb & Sons, L.L.C. | $116 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-23 | JAZZ PHARMACEUTICALS INC. | $272 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-07-22 | PFIZER INC. | $30 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-07-17 | AstraZeneca Pharmaceuticals LP | $106 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-07-17 | Caris MPI, Inc. | $23 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-07-07 | Lilly USA, LLC | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JAYPIRCA Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $620 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $303 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $60 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $59 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $24 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-28 | Incyte Corporation | $22 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-27 | Incyte Corporation | $139 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-27 | Incyte Corporation | $24 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-06-25 | Daiichi Sankyo Inc. | $670 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-20 | Amgen Inc. | $3,864 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KYPROLIS Drug, Oncology | 2025 | |
| 2025-06-17 | Amgen Inc. | $117 | Food and Beverage | In-kind items and services | KYPROLIS Drug, Oncology | 2025 | |
| 2025-06-16 | GlaxoSmithKline, LLC. | $450 | Consulting Fee | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-06-12 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-06 | AstraZeneca Pharmaceuticals LP | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENHERTU Biological, Oncology | 2025 | |
| 2025-06-03 | AstraZeneca Pharmaceuticals LP | $92 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-06-02 | AstraZeneca Pharmaceuticals LP | $115 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-02 | Bayer Healthcare Pharmaceuticals Inc. | $98 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-01 | Novartis Pharmaceuticals Corporation | $96 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-05-30 | Incyte Corporation | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-05-30 | Daiichi Sankyo Inc. | $84 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-05-28 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $838 | Travel and Lodging | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $780 | Travel and Lodging | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $126 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-05-16 | Geron Corporation | $30 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-05-15 | Astellas Pharma US Inc | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-05-15 | Astellas Pharma US Inc | $931 | Travel and Lodging | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-05-15 | Astellas Pharma US Inc | $121 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-05-15 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-05-12 | Daiichi Sankyo Inc. | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-05-12 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-08 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-06 | Daiichi Sankyo Inc. | $1,596 | Travel and Lodging | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-05-06 | Daiichi Sankyo Inc. | $124 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-05-02 | Medtronic, Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OSTEOCOOL RF ABLATION SYSTEM Device, Neuro Pain (includes Interventional) | 2025 | |
| 2025-04-25 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENHERTU Biological, Oncology | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-04-22 | Medtronic, Inc. | $859 | Travel and Lodging | In-kind items and services | OSTEOCOOL RF ABLATION SYSTEM Device, Neuro Pain (includes Interventional) | 2025 | |
| 2025-04-22 | Medtronic, Inc. | $112 | Food and Beverage | In-kind items and services | OSTEOCOOL RF ABLATION SYSTEM Device, Neuro Pain (includes Interventional) | 2025 | |
| 2025-04-16 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-15 | Astellas Pharma US Inc | $3,425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-04-15 | Astellas Pharma US Inc | $120 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-04-10 | Daiichi Sankyo Inc. | $650 | Consulting Fee | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | 2025 | |
| 2025-04-10 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-04-08 | Daiichi Sankyo Inc. | $678 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-08 | Daiichi Sankyo Inc. | $96 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-07 | GlaxoSmithKline, LLC. | $2,800 | Consulting Fee | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-03-28 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-03-26 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-03-25 | Daiichi Sankyo Inc. | $1,330 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-03-25 | Daiichi Sankyo Inc. | $97 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-03-25 | Daiichi Sankyo Inc. | $11 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-03-21 | Karyopharm Therapeutics Inc. | $136 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-03-11 | Genentech, Inc. | $15 | Food and Beverage | In-kind items and services | Itovebi Biological, BioOncology | 2025 | |
| 2025-03-06 | Adaptive Biotechnologies Corporation | $21 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-03-04 | Astellas Pharma US Inc | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-03-04 | Astellas Pharma US Inc | $2,088 | Travel and Lodging | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-03-04 | Astellas Pharma US Inc | $324 | Travel and Lodging | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-03-04 | Astellas Pharma US Inc | $140 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-02-25 | AstraZeneca Pharmaceuticals LP | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-02-21 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $110 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-12 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-02-07 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENHERTU Biological, Oncology | 2025 | |
| 2025-01-28 | AstraZeneca Pharmaceuticals LP | $1,042 | Travel and Lodging | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-01-28 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-01-22 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-01-15 | Novocure Inc. | $18 | Food and Beverage | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2025 | |
| 2025-01-10 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-01-09 | Cardinal Health 110 LLC | $275 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-27 | Astellas Pharma US Inc | $685 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vyloy Drug, Oncology | 2024 | |
| 2024-12-18 | JAZZ PHARMACEUTICALS INC. | $460 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2024 | |
| 2024-12-16 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-13 | PFIZER INC. | $1,620 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, Oncology | 2024 | |
| 2024-12-12 | Daiichi Sankyo Inc. | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-12-10 | Daiichi Sankyo Inc. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-12-10 | Daiichi Sankyo Inc. | $1,609 | Travel and Lodging | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-10 | Daiichi Sankyo Inc. | $97 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-10 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-12-10 | Daiichi Sankyo Inc. | $21 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-12-09 | GlaxoSmithKline, LLC. | $2,800 | Consulting Fee | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-12-05 | Tempus AI, Inc | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-12-03 | Daiichi Sankyo Inc. | $694 | Travel and Lodging | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-12-03 | Daiichi Sankyo Inc. | $66 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-12-02 | AstraZeneca Pharmaceuticals LP | $2,010 | Consulting Fee | Cash or cash equivalent | Truqap Drug, Oncology | 2024 | |
| 2024-11-24 | GENZYME CORPORATION | $535 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SARCLISA Biological, Oncology | 2024 | |
| 2024-11-20 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENHERTU Biological, Oncology | 2024 | |
| 2024-11-20 | Novocure Inc. | $26 | Food and Beverage | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2024 | |
| 2024-11-18 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 |
The latest 200 records of 1,516.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $90 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2020-12-21 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $50 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-16 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-16 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2019-12-18 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $41 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-09-05 | Merck Sharp & Dohme LLC | SOUTHEAST COR NCORP | $500 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Mechanicsville, VA, county Hanover County, VA, state Virginia; placed by its city name.
| Measure | Place (city or town) Mechanicsville, VA | County Hanover County, VA | State Virginia |
|---|---|---|---|
| Population B01003 | 38,683 | 112,879 | 8,705,170 |
| Population, 2020 census P1 | 39,482 | 109,979 | 8,631,393 |
| Median age B01002 | 41.8 | 42.7 | 39.0 |
| Under 18 B01001 | 21.8% | 21.6% | 21.7% |
| 65 and over B01001 | 19.8% | 19.2% | 16.7% |
| Households B11001 | 15,337 | 42,688 | 3,365,732 |
| Foreign born B05002 | 3.8% | 4.3% | 13.1% |
| Median household income B19013 | $98,595 | $112,805 | $93,170 |
| Median family income B19113 | $120,441 | $132,791 | $115,213 |
| Per capita income B19301 | $45,231 | $53,490 | $50,666 |
| Poverty rate B17001 | 5.2% | 5.7% | 9.9% |
| Unemployment rate B23025 | 1.9% | 2.7% | 4.3% |
| Civilian labor force B23025 | 20,438 | 60,013 | 4,468,236 |
| Mean commute (minutes) B08013 | 23.9 | 26.9 | 27.3 |
| Bachelor's degree or higher B15003 | 35.8% | 42.7% | 42.2% |
| Housing units B25001 | 15,947 | 44,589 | 3,684,756 |
| Owner-occupied B25003 | 75.5% | 82.1% | 67.3% |
| Renters B25003 | 24.5% | 17.9% | 32.7% |
| Median home value B25077 | $351,000 | $400,400 | $383,700 |
| Median gross rent B25064 | $1,724 | $1,591 | $1,579 |
| White, not Hispanic B03002 | 82.3% | 80.7% | 58.4% |
| Black B03002 | 8.2% | 8.3% | 18.3% |
| Hispanic or Latino B03002 | 2.8% | 4.0% | 11.0% |
| Asian B03002 | 1.5% | 2.1% | 6.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Mechanicsville, VA.
Comments